PharmacoEconomics - Open

2017 - 2025

Current editor(s): Timothy Wrightson and Christopher Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 3, issue 4, 2019

Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations pp. 433-435

Geert W. J. Frederix

A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers pp. 437-451

Naghmeh Foroutan, Jean-Eric Tarride, Feng Xie, Fergal Mills and Mitchell Levine

Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 453-461

Nigel Fleeman, James Mahon, Sarah Nevitt, Rui Duarte, Angela Boland, Eleanor Kotas, Yenal Dundar, Joanne McEntee and Sajjad Ahmad

Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review pp. 463-478

Pablo E. Pergola, Roberto Pecoits-Filho, Wolfgang C. Winkelmayer, Bruce Spinowitz, Samuel Rochette, Philippe Thompson-Leduc, Patrick Lefebvre, Gigi Shafai, Ana Bozas, Myrlene Sanon and Holly B. Krasa

A Systematic Review of the Health Economics of Pompe Disease pp. 479-493

Benedikt Schoser, Andreas Hahn, Emma James, Digant Gupta, Matthew Gitlin and Suyash Prasad

Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial pp. 495-504

Laura Pirhonen, Kristian Bolin, Elisabeth Hansson Olofsson, Andreas Fors, Inger Ekman, Karl Swedberg and Hanna Gyllensten

Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM) pp. 505-515

Osvaldo Ulises Garay, Marie Libérée Nishimwe, Marwân-al-Qays Bousmah, Asmaa Janah, Pierre-Marie Girard, Geneviève Chêne, Laetitia Moinot, Luis Sagaon-Teyssier, Jean-Luc Meynard, Bruno Spire and Sylvie Boyer

National Health Insurance Databases in Indonesia, Vietnam and the Philippines pp. 517-526

Junice Yi Siu Ng, Royasia Viki Ramadani, Donni Hendrawan, Duong Tuan Duc and Pham Huy Tuan Kiet

Use of Initial Noninvasive Cardiac Testing and Association with Downstream Healthcare Resource: A Retrospective Review of Resources Used Across a 12-Month Window for Probable Type I Myocardial Infarction Patients pp. 527-535

Dana Villines, Wm. Thomas Summerfelt, James R. Spalding, Therese M. Kitt, Rita M. Kristy and Christy R. Houle

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada pp. 537-550

Pierre Johansen, Jonas Håkan-Bloch, Aiden R. Liu, Peter G. Bech, Sofie Persson and Lawrence A. Leiter

Using Time Trade-Off Methods to Elicit Short-Term Utilities Associated with Treatments for Bulbar Urethral Stricture pp. 551-558

Jing Shen, Matthew Breckons, Luke Vale and Robert Pickard

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK pp. 559-570

Claire Telford, Evelina Bertranou, Samuel Large, Hilary Phelps, Mattias Ekman and Christopher Livings

Using a Discrete-Choice Experiment to Estimate the Preferences of Clinical Practitioners for a Novel Non-invasive Device for Diagnosis of Peripheral Arterial Disease in Primary Care pp. 571-581

Yemi Oluboyede, Laura Ternent, Luke Vale and John Allen

Analysis of Health Technology Assessments of Orphan Drugs in Ireland from 2012 to 2017 pp. 583-589

Cara Usher, Laura McCullagh, Lesley Tilson and Michael Barry

The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta pp. 591-597

Ilke Akpinar, Arto Ohinmaa, Lars Thording, Dat T. Tran, Richard N. Fedorak, Lawrence Richer and Philip Jacobs

Long-Term Inpatient Hospital Utilisation and Costs (2007–2008 to 2015–2016) for Publicly Waitlisted Bariatric Surgery Patients in an Australian Public Hospital System Based on Australia’s Activity-Based Funding Model pp. 599-618

Julie Campbell, Martin Hensher, Daniel Davies, Matthew Green, Barry Hagan, Ian Jordan, Alison Venn, Alexandr Kuzminov, Amanda Neil, Stephen Wilkinson and Andrew J. Palmer

Smart Pump–Electronic Health Record (EHR) Interoperability with Auto-Documentation is Associated with Increased Submission of Infusion-Therapy Billing Claims at a Community Hospital pp. 619-629

Tina M. Suess, John W. Beard, Michael Ripchinski, Matthew Eberts, Kevin Patrick and Leo J. P. Tharappel

A Cost Analysis of Haemodialysis and Peritoneal Dialysis for the Management of End-Stage Renal Failure At an Academic Hospital in Pretoria, South Africa pp. 631-641

Letlhogonolo Makhele, Moliehi Matlala, Mncengeli Sibanda, Antony P. Martin and Brian Godman

Indonesian Social Health Insurance Sample Data are Now Available and Accessible for Research pp. 643-645

Anis Fuad

Correction to: A Cost Analysis of Haemodialysis and Peritoneal Dialysis for the Management of End-Stage Renal Failure At an Academic Hospital in Pretoria, South Africa pp. 647-647

Letlhogonolo Makhele, Moliehi Matlala, Mncengeli Sibanda, Antony P. Martin and Brian Godman

Volume 3, issue 3, 2019

Extending Life in Duchenne Muscular Dystrophy: Implications for Appraisals of Cost-Effectiveness pp. 279-280

Erik Landfeldt

Use of Decision Modelling in Economic Evaluations of Diagnostic Tests: An Appraisal and Review of Health Technology Assessments in the UK pp. 281-291

Yaling Yang, Lucy Abel, James Buchanan, Thomas Fanshawe and Bethany Shinkins

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 293-302

Nigel Fleeman, Adrian Bagust, Rui Duarte, Marty Richardson, Sarah Nevitt, Angela Boland, Eleanor Kotas, Joanne McEntee and Nicky Thorp

Evolution of Average European Medicine Prices: Implications for the Methodology of External Price Referencing pp. 303-309

Sabine Vogler, Peter Schneider and Nina Zimmermann

The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method pp. 311-319

Najme Moradi, Arash Rashidian, Shirin Nosratnejad, Alireza Olyaeemanesh, Marzieh Zanganeh and Leila Zarei

Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada pp. 321-331

Peter L. Quon, Ying Xiao, Sonja Sorensen and Amir Abbas Tahami Monfared

Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study pp. 333-342

Luis Manuel Entrenas Costa, Francisco Casas-Maldonado, José Gregorio Soto Campos, Alicia Padilla-Galo, Alberto Levy, Francisco Javier Álvarez Gutiérrez, Ana P. Gómez-Bastero Fernández, Concepción Morales-García, Rocío Gallego Domínguez, Gustavo Villegas Sánchez, Luis Mateos Caballero, Antonio Pereira-Vega, Cayo García Polo, Gerardo Pérez Chica and Juan José Martín Villasclaras

Estimated Versus Observed Expenditure Associated with Medicines Recommended by the All Wales Medicines Strategy Group pp. 343-350

Stuart Keeping, Paul N. Deslandes, Kathryn E. Haines and Philip A. Routledge

The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q pp. 351-358

Dawn Lee, Nic Brereton, Sujith Dhanasiri and Austin Kulasekararaj

Remote Monitoring of Patient-Reported Outcomes in Ulcerative Colitis: A Prospective Real-World Pilot Study pp. 359-365

Shaji Sebastian, Jenna Roberts, John Waller, Davneet Judge, Chloe Brown, Ruth Davies and Sumesh Kachroo

Associations between Health-Related Quality of Life and Self-Reported Emergency Room Department Visits and Inpatient Hospitalizations: Insights from a Secondary Data Analysis of Patients with Light-Chain (AL) Amyloidosis pp. 367-375

Kristen L. McCausland, Avery A. Rizio, Michelle K. White, Martha S. Bayliss and Tiffany P. Quock

Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma pp. 377-390

Ash Bullement, Paul Nathan, Anna Willis, Amerah Amin, Cameron Lilley, Ceilidh Stapelkamp, Anthony Hatswell, Chris Pescott and Murtuza Bharmal

Cost of Treatment of Valvular Heart Disease at a Tertiary Hospital in North India: Policy Implications pp. 391-402

Shankar Prinja, Yashpaul Sharma, Jyoti Dixit, Shyam Kumar Singh Thingnam and Rajesh Kumar

A Review of Issues Affecting the Efficiency of Decision Making in the NICE Single Technology Appraisal Process pp. 403-410

M. J. Walton, J. O’Connor, C. Carroll, L. Claxton and R. Hodgson

Costs of Acute Headache Medication Use and Productivity Losses Among Patients with Migraine: Insights from Three Randomized Controlled Trials pp. 411-417

Joshua K. Porter, Gian Luca Di Tanna, Richard B. Lipton, Sandhya Sapra and Guillermo Villa

All-Male Panels and Gender Diversity of Issue Panels and Plenary Sessions at ISPOR Europe pp. 419-422

Jacoline C. Bouvy and Michelle Mujoomdar

All Male Panels and Other Diversity Considerations for ISPOR pp. 423-426

Nancy Devlin

Correction to: Conducting a Time Trade-Off Study Alongside a Clinical Trial: A Case Study and Recommendations pp. 427-427

Jing Shen, Sarah Hill, David Mott, Matthew Breckons, Luke Vale and Rob Pickard

Volume 3, issue 2, 2019

Evaluating the Outcomes Associated with Genomic Sequencing: A Roadmap for Future Research pp. 129-132

James Buchanan and Sarah Wordsworth

Working with Patients and Members of the Public: Informing Health Economics in Child Health Research pp. 133-141

Rebecca Kandiyali, Annie Hawton, Christie Cabral, Julie Mytton, Valerie Shilling, Christopher Morris and Jenny Ingram

Measuring the Benefits of Decision Aids for Economic Evaluation pp. 143-150

Thomas Butt

Strimvelis® for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation pp. 151-161

Emily South, Edward Cox, Nick Meader, Nerys Woolacott and Susan Griffin

Uterotonic Drugs for the Prevention of Postpartum Haemorrhage: A Cost-Effectiveness Analysis pp. 163-176

Karen Pickering, Ioannis D. Gallos, Helen Williams, Malcolm J. Price, Abi Merriel, David Lissauer, Aurelio Tobias, G. Justus Hofmeyr, Arri Coomarasamy and Tracy E. Roberts

Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate pp. 177-188

Bruno Emond, Kruti Joshi, Antoine C. El Khoury, Marie-Hélène Lafeuille, Dominic Pilon, Neeta Tandon, Hela Romdhani and Patrick Lefebvre

Cost Comparison of Single-Use Versus Reusable Bronchoscopes Used for Percutaneous Dilatational Tracheostomy pp. 189-195

Anne Sohrt, Lars Ehlers, Flemming Witt Udsen, Anders Mærkedahl and Brendan A. McGrath

The Psychometric Properties of a Self-Administered, Open-Source Module for Valuing Metastatic Epidural Spinal Cord Compression Utilities pp. 197-204

Markian Pahuta, Aaron Frombach, Emile Hashem, Stewart Spence, Christina Sun, Eugene K. Wai, Joel Werier, Carl Walraven and Doug Coyle

High Healthcare Resource Use in Hospitalized Patients with a Diagnosis of Spinal Muscular Atrophy Type 1 (SMA1): Retrospective Analysis of the Kids’ Inpatient Database (KID) pp. 205-213

Jessica Cardenas, Melissa Menier, Marjet D. Heitzer and Douglas M. Sproule

Does Structured Exercise Improve Cognitive Impairment in People with Mild to Moderate Dementia? A Cost-Effectiveness Analysis from a Confirmatory Randomised Controlled Trial: The Dementia and Physical Activity (DAPA) Trial pp. 215-227

Iftekhar Khan, Stavros Petrou, Kamran Khan, Dipesh Mistry, Ranjit Lall, Bart Sheehan and Sarah Lamb

Time and Cost of Hospitalisation for Salvage Therapy in Adults with Philadelphia Chromosome-Negative B Cell Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in Spain pp. 229-235

Blanca Boluda, Rebeca Rodríguez-Veiga, David Martínez-Cuadrón, Ignacio Lorenzo, Jaime Sanz, Ana Regadera, Amparo Sempere, Leonor Senent, Jose Vicente Cervera, Pilar Solves, John Reitan, Salvador Gea, Miguel Angel Sanz and Pau Montesinos

Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States pp. 237-245

Jill A. Bell, Aaron Galaznik, Marlo Blazer, Huai-Che Shih, Eileen Farrelly, Augustina Ogbonnaya, Michael Eaddy, Robert J. Fram and Douglas V. Faller

Economics of Acromegaly Treatment in Brazil: A Budget Impact Analysis of Pituitary Surgery Compared with Long-Term Octreotide LAR pp. 247-254

Lara Benigno Porto, Ivan Ricardo Zimmermann and Luciana Ansaneli Naves

Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan pp. 255-264

Timothy Bolt, Hisanori Kobayashi and Jörg Mahlich

Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes pp. 265-272

Anne Sohrt, Anders Mærkedahl and William V. Padula

Correction to: Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes pp. 273-273

Anne Sohrt, Anders Mærkedahl and William V. Padula

Correction to: Cost-Effectiveness Analysis of Single-Use EEG Cup Electrodes Compared with Reusable EEG Cup Electrodes pp. 275-275

Anne Sohrt, Anders Mærkedahl and William V. Padula

Correction to: Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease pp. 277-277

James Lomas, Miqdad Asaria, Laura Bojke, Chris P. Gale, Gerry Richardson and Simon Walker

Volume 3, issue 1, 2019

Value Assessment Frameworks in the United States: A Call for Patient Engagement pp. 1-3

Vakaramoko Diaby, Askal A. Ali and Alberto J. Montero

Conducting a Time Trade-Off Study Alongside a Clinical Trial: A Case Study and Recommendations pp. 5-20

Jing Shen, Sarah Hill, David Mott, Matthew Breckons, Luke Vale and Rob Pickard

Systematic Review of Economic Models Used to Compare Techniques for Detecting Peripheral Arterial Disease pp. 21-30

Eoin Moloney, Joanne O’Connor, Dawn Craig, Shannon Robalino, Alexandros Chrysos, Mehdi Javanbakht, Andrew Sims, Gerard Stansby, Scott Wilkes and John Allen

Accommodation and Health Costs of Deinstitutionalized People with Mental Illness Living in Residential Services in Brazil pp. 31-42

Denise Razzouk

Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England pp. 43-54

D. Lee, A. Amadi, J. Sabater, J. Ellis, H. Johnson, S. Kotapati, S. McNamara, A. Walker, M. Cooper, K. Patterson, N. Roskell and Y. Meng

Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0–9 Years with Pertussis in Catalonia (Spain) pp. 55-69

Pedro Plans-Rubió, Encarna Navas, Pere Godoy, Gloria Carmona, Angela Domínguez, Mireia Jané, Carmen Muñoz-Almagro and Pedro Brotons

Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD) pp. 71-80

Meryl Brod, Jane F. Beck, Lise Højbjerre, Donald M. Bushnell, Johan Erpur Adalsteinsson, Lars Wilkinson and Michael Højby Rasmussen

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use pp. 81-91

Alex Diamantopoulos, Toby M. Maher, Nils Schoof, Dirk Esser and Corinne LeReun

Cost Effectiveness of Long-Term Incobotulinumtoxin-A Treatment in the Management of Post-stroke Spasticity of the Upper Limb from the Australian Payer Perspective pp. 93-102

Koji Makino, Dominic Tilden, Carmel Guarnieri, Mia Mudge and Ian J. Baguley

International HTA Experience with Targeted Therapy Approvals for Lung Cancer pp. 103-117

Fatma Maraiki, Joshua Byrnes, H. Tuffaha and M. Hinder

Evaluation of the Impact of an Institution-Specific Dofetilide Initiation Protocol on Mean Hospital Length of Stay and Cost for Dofetilide Initiation pp. 119-126

Steven P. Kennedy, Hanna Iaizzo, Evgueni Fayn and Dalip Singh

Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England pp. 127-127

D. Lee, A. Amadi, J. Sabater, J. Ellis, H. Johnson, S. Kotapati, S. McNamara, A. Walker, M. Cooper, K. Patterson, N. Roskell and Y. Meng